TW
PDLI

TrinityPoint Wealth’s PDL BioPharma, Inc. PDLI Stock Holding History

TrinityPoint Wealth’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,947
Closed -$38K – 242
2020
Q3 		$38K Buy
11,947
+246
+2% +$786 0.01% 214
2020
Q2 		$34K Hold
11,701
– – 0.01% 204
2020
Q1 		$33K Sell
11,701
-681
-5% -$2.19K 0.01% 192
2019
Q4 		$40K Sell
12,382
-2,689
-18% -$7.81K 0.01% 210
2019
Q3 		$43K Buy
15,071
+632
+4% +$1.69K 0.02% 207
2019
Q2 		$45K Buy
14,439
+109
+0.8% +$354 0.02% 170
2019
Q1 		$53K Buy
+14,330
New +$48.4K 0.03% 180

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

TrinityPoint Wealth's PDLI Position: Q4 2020 in Review

TrinityPoint Wealth sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 11,947 shares — an estimated $38K sold.

TrinityPoint Wealth first reported a position in PDLI in Q1 2019 and held it in 7 quarters. The position peaked at $53K in Q1 2019. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • TrinityPoint Wealth reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • TrinityPoint Wealth sold 11,947 PDL BioPharma, Inc. shares in Q4 2020, an estimated $38K.
  • TrinityPoint Wealth first reported a position in PDL BioPharma, Inc. in Q1 2019 and held it in 7 quarters.
  • TrinityPoint Wealth's PDL BioPharma, Inc. position peaked at $53K in Q1 2019.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on TrinityPoint Wealth's 13F filing for Q4 2020, filed 10 Feb 2021.